Mitsubishi, Perlegen Strike Licensing Agreement for MCC-555 Antidiabetic Agent

Mitsubishi Pharma and Perlegen Sciences jointly announced that they have entered into a licensing agreement for MCC-555, a new antidiabetic agent. Under the terms of the agreement, Perlegen will retain the exclusive worldwide rights, excluding Asia, to develop and commercialize MCC-555.

Japan Corporate News Network (http://japancorp.net/Article.Asp?Art_ID=9845)